SRPT Annual CFF
$125.00 M
-$107.50 M-46.24%
31 December 2023
Summary:
As of January 22, 2025, SRPT annual cash flow from financing activities is $125.00 million, with the most recent change of -$107.50 million (-46.24%) on December 31, 2023. During the last 3 years, it has fallen by -$557.32 million (-81.68%). SRPT annual CFF is now -85.92% below its all-time high of $888.08 million, reached on December 31, 2017.SRPT Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SRPT Quarterly CFF
$13.76 M
-$26.16 M-65.54%
30 September 2024
Summary:
As of January 22, 2025, SRPT quarterly cash flow from financing activities is $13.76 million, with the most recent change of -$26.16 million (-65.54%) on September 30, 2024. Over the past year, it has increased by +$11.81 million (+608.03%). SRPT quarterly CFF is now -97.50% below its all-time high of $549.25 million, reached on December 31, 2021.SRPT Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SRPT TTM CFF
$77.76 M
-$1.65 M-2.08%
30 September 2024
Summary:
As of January 22, 2025, SRPT TTM cash flow from financing activities is $77.76 million, with the most recent change of -$1.65 million (-2.08%) on September 30, 2024. Over the past year, it has dropped by -$47.25 million (-37.80%). SRPT TTM CFF is now -91.57% below its all-time high of $921.87 million, reached on June 30, 2018.SRPT TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SRPT Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -46.2% | +608.0% | -37.8% |
| 3 y3 years | -81.7% | -93.6% | -89.9% |
| 5 y5 years | -76.4% | -93.6% | -89.9% |
SRPT Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -77.7% | at low | -97.5% | +3958.1% | -89.9% | +71.5% |
| 5 y | 5-year | -81.7% | at low | -97.5% | +3958.1% | -89.9% | +71.5% |
| alltime | all time | -85.9% | >+9999.0% | -97.5% | +157.4% | -91.6% | >+9999.0% |
Sarepta Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $13.76 M(-65.5%) | $77.76 M(-2.1%) |
| June 2024 | - | $39.92 M(+80.3%) | $79.41 M(+75.1%) |
| Mar 2024 | - | $22.14 M(+1039.5%) | $45.35 M(-63.7%) |
| Dec 2023 | $125.00 M(-46.2%) | $1.94 M(-87.4%) | $125.00 M(-6.6%) |
| Sept 2023 | - | $15.40 M(+162.8%) | $133.81 M(-60.0%) |
| June 2023 | - | $5.86 M(-94.2%) | $334.83 M(+1.7%) |
| Mar 2023 | - | $101.80 M(+847.0%) | $329.31 M(+41.6%) |
| Dec 2022 | $232.51 M(-58.6%) | $10.75 M(-95.0%) | $232.51 M(-69.8%) |
| Sept 2022 | - | $216.43 M(>+9900.0%) | $771.01 M(+37.6%) |
| June 2022 | - | $339.00 K(-93.2%) | $560.48 M(-0.6%) |
| Mar 2022 | - | $4.99 M(-99.1%) | $563.67 M(+0.4%) |
| Dec 2021 | $561.57 M(-17.7%) | $549.25 M(+9206.1%) | $561.57 M(+65.5%) |
| Sept 2021 | - | $5.90 M(+67.4%) | $339.26 M(-3.7%) |
| June 2021 | - | $3.53 M(+21.9%) | $352.14 M(-3.8%) |
| Mar 2021 | - | $2.89 M(-99.1%) | $366.19 M(-46.3%) |
| Dec 2020 | $682.32 M(+6.2%) | $326.94 M(+1640.0%) | $682.32 M(+11.4%) |
| Sept 2020 | - | $18.79 M(+6.9%) | $612.35 M(+2.9%) |
| June 2020 | - | $17.57 M(-94.5%) | $595.30 M(+1.9%) |
| Mar 2020 | - | $319.02 M(+24.1%) | $584.01 M(-9.1%) |
| Dec 2019 | $642.55 M(+21.2%) | $256.97 M(>+9900.0%) | $642.55 M(-29.1%) |
| Sept 2019 | - | $1.73 M(-72.5%) | $906.87 M(+2.9%) |
| June 2019 | - | $6.29 M(-98.3%) | $881.18 M(-2.1%) |
| Mar 2019 | - | $377.56 M(-27.6%) | $900.24 M(+69.8%) |
| Dec 2018 | $530.15 M(-40.3%) | $521.28 M(-2276.1%) | $530.15 M(+2.8%) |
| Sept 2018 | - | -$23.95 M(-194.5%) | $515.68 M(-44.1%) |
| June 2018 | - | $25.35 M(+239.3%) | $921.87 M(+3.0%) |
| Mar 2018 | - | $7.47 M(-98.5%) | $895.35 M(+0.8%) |
| Dec 2017 | $888.08 M(+134.9%) | $506.81 M(+32.6%) | $888.08 M(+128.6%) |
| Sept 2017 | - | $382.24 M(<-9900.0%) | $388.56 M(+14.3%) |
| June 2017 | - | -$1.17 M(-669.9%) | $340.03 M(-10.4%) |
| Mar 2017 | - | $206.00 K(-97.2%) | $379.37 M(+0.3%) |
| Dec 2016 | $378.13 M(+155.8%) | $7.29 M(-97.8%) | $378.13 M(-23.8%) |
| Sept 2016 | - | $333.71 M(+774.3%) | $496.42 M(+202.2%) |
| June 2016 | - | $38.17 M(-3780.5%) | $164.28 M(+12.2%) |
| Mar 2016 | - | -$1.04 M(-100.8%) | $146.37 M(-1.0%) |
| Dec 2015 | $147.81 M(+41.9%) | $125.58 M(+7868.0%) | $147.81 M(+564.1%) |
| Sept 2015 | - | $1.58 M(-92.2%) | $22.26 M(-14.7%) |
| June 2015 | - | $20.25 M(+4887.7%) | $26.09 M(-74.4%) |
| Mar 2015 | - | $406.00 K(+1591.7%) | $101.87 M(-2.2%) |
| Dec 2014 | $104.16 M(-28.5%) | $24.00 K(-99.6%) | $104.16 M(-1.8%) |
| Sept 2014 | - | $5.41 M(-94.4%) | $106.10 M(-55.7%) |
| June 2014 | - | $96.03 M(+3470.0%) | $239.70 M(+64.9%) |
| Mar 2014 | - | $2.69 M(+36.9%) | $145.39 M(-0.2%) |
| Dec 2013 | $145.67 M(-18.4%) | $1.97 M(-98.6%) | $145.67 M(-51.6%) |
| Sept 2013 | - | $139.01 M(+7977.5%) | $300.96 M(+64.2%) |
| June 2013 | - | $1.72 M(-42.1%) | $183.33 M(+1.0%) |
| Mar 2013 | - | $2.97 M(-98.1%) | $181.59 M(+1.7%) |
| Dec 2012 | $178.60 M(+452.9%) | $157.25 M(+635.5%) | $178.60 M(+737.7%) |
| Sept 2012 | - | $21.38 M(<-9900.0%) | $21.32 M(<-9900.0%) |
| June 2012 | - | -$21.00 K(+5.0%) | -$50.00 K(-100.2%) |
| Mar 2012 | - | -$20.00 K(0.0%) | $32.18 M(-0.4%) |
| Dec 2011 | $32.30 M(+1200.3%) | -$20.00 K(-281.8%) | $32.30 M(-0.1%) |
| Sept 2011 | - | $11.00 K(-100.0%) | $32.34 M(-7.1%) |
| June 2011 | - | $32.21 M(>+9900.0%) | $34.81 M(+1238.9%) |
| Mar 2011 | - | $96.00 K(+464.7%) | $2.60 M(+4.7%) |
| Dec 2010 | $2.48 M | $17.00 K(-99.3%) | $2.48 M(-0.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2010 | - | $2.49 M(>+9900.0%) | $2.50 M(-92.3%) |
| June 2010 | - | $0.00(-100.0%) | $32.31 M(+0.0%) |
| Mar 2010 | - | -$20.00 K(-160.6%) | $32.30 M(-32.4%) |
| Dec 2009 | $47.77 M(<-9900.0%) | $33.00 K(-99.9%) | $47.77 M(+0.0%) |
| Sept 2009 | - | $32.30 M(<-9900.0%) | $47.76 M(+209.3%) |
| June 2009 | - | -$12.00 K(-100.1%) | $15.44 M(-0.2%) |
| Mar 2009 | - | $15.45 M(>+9900.0%) | $15.48 M(<-9900.0%) |
| Dec 2008 | -$32.00 K(-100.2%) | $23.10 K(-227.6%) | -$32.00 K(-100.2%) |
| Sept 2008 | - | -$18.10 K(-169.6%) | $18.62 M(-0.1%) |
| June 2008 | - | $26.00 K(-141.3%) | $18.64 M(-0.2%) |
| Mar 2008 | - | -$63.00 K(-100.3%) | $18.68 M(-0.3%) |
| Dec 2007 | $18.74 M(+129.6%) | $18.68 M(>+9900.0%) | $18.75 M(>+9900.0%) |
| Sept 2007 | - | $5200.00(-91.8%) | $141.90 K(-6.5%) |
| June 2007 | - | $63.60 K(>+9900.0%) | $151.70 K(-20.9%) |
| Mar 2007 | - | $0.00(-100.0%) | $191.70 K(-97.7%) |
| Dec 2006 | $8.16 M(-81.2%) | $73.10 K(+387.3%) | $8.16 M(-72.1%) |
| Sept 2006 | - | $15.00 K(-85.5%) | $29.24 M(+0.1%) |
| June 2006 | - | $103.60 K(-98.7%) | $29.22 M(+0.1%) |
| Mar 2006 | - | $7.97 M(-62.3%) | $29.19 M(-32.9%) |
| Dec 2005 | $43.53 M(+515.3%) | $21.15 M(>+9900.0%) | $43.53 M(+94.2%) |
| Sept 2005 | - | $0.00(-100.0%) | $22.41 M(0.0%) |
| June 2005 | - | $68.00 K(-99.7%) | $22.41 M(+0.1%) |
| Mar 2005 | - | $22.31 M(>+9900.0%) | $22.40 M(+216.6%) |
| Dec 2004 | $7.07 M(-79.8%) | $34.60 K(>+9900.0%) | $7.07 M(-66.3%) |
| Sept 2004 | - | $0.00(-100.0%) | $21.00 M(-0.6%) |
| June 2004 | - | $53.50 K(-99.2%) | $21.11 M(-49.8%) |
| Mar 2004 | - | $6.99 M(-49.9%) | $42.04 M(+19.8%) |
| Dec 2003 | $35.08 M(+59.6%) | $13.96 M(>+9900.0%) | $35.08 M(+63.6%) |
| Sept 2003 | - | $118.80 K(-99.4%) | $21.44 M(+0.6%) |
| June 2003 | - | $20.98 M(>+9900.0%) | $21.30 M(+5058.0%) |
| Mar 2003 | - | $26.20 K(-91.8%) | $413.00 K(-98.1%) |
| Dec 2002 | $21.98 M(+104.2%) | $318.30 K(-1868.3%) | $21.98 M(+0.5%) |
| Sept 2002 | - | -$18.00 K(-120.8%) | $21.86 M(-1.5%) |
| June 2002 | - | $86.50 K(-99.6%) | $22.19 M(-31.4%) |
| Mar 2002 | - | $21.59 M(>+9900.0%) | $32.35 M(+200.6%) |
| Dec 2001 | $10.76 M(-60.8%) | $204.00 K(-34.7%) | $10.76 M(+1.4%) |
| Sept 2001 | - | $312.60 K(-96.9%) | $10.61 M(-69.6%) |
| June 2001 | - | $10.24 M(>+9900.0%) | $34.96 M(+39.6%) |
| Mar 2001 | - | $6800.00(-87.4%) | $25.03 M(-8.8%) |
| Dec 2000 | $27.44 M(+234.6%) | $54.00 K(-99.8%) | $27.44 M(-22.9%) |
| Sept 2000 | - | $24.66 M(+7773.7%) | $35.59 M(+225.7%) |
| June 2000 | - | $313.20 K(-87.0%) | $10.93 M(+3.0%) |
| Mar 2000 | - | $2.41 M(-70.6%) | $10.61 M(+29.4%) |
| Dec 1999 | $8.20 M(+4000.0%) | $8.20 M(>+9900.0%) | $8.20 M(>+9900.0%) |
| Sept 1999 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 1999 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 1999 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Dec 1998 | $200.00 K(-98.9%) | $0.00(0.0%) | $200.00 K(-77.8%) |
| Sept 1998 | - | $0.00(0.0%) | $900.00 K(-67.9%) |
| June 1998 | - | $0.00(-100.0%) | $2.80 M(-84.9%) |
| Mar 1998 | - | $200.00 K(-71.4%) | $18.60 M(+2.2%) |
| Dec 1997 | $18.20 M(+366.7%) | $700.00 K(-63.2%) | $18.20 M(+4.0%) |
| Sept 1997 | - | $1.90 M(-88.0%) | $17.50 M(+12.2%) |
| June 1997 | - | $15.80 M(-8000.0%) | $15.60 M(-7900.0%) |
| Mar 1997 | - | -$200.00 K | -$200.00 K |
| Dec 1996 | $3.90 M | - | - |
FAQ
- What is Sarepta Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Sarepta Therapeutics?
- What is Sarepta Therapeutics annual CFF year-on-year change?
- What is Sarepta Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly CFF year-on-year change?
- What is Sarepta Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Sarepta Therapeutics?
- What is Sarepta Therapeutics TTM CFF year-on-year change?
What is Sarepta Therapeutics annual cash flow from financing activities?
The current annual CFF of SRPT is $125.00 M
What is the all time high annual CFF for Sarepta Therapeutics?
Sarepta Therapeutics all-time high annual cash flow from financing activities is $888.08 M
What is Sarepta Therapeutics annual CFF year-on-year change?
Over the past year, SRPT annual cash flow from financing activities has changed by -$107.50 M (-46.24%)
What is Sarepta Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of SRPT is $13.76 M
What is the all time high quarterly CFF for Sarepta Therapeutics?
Sarepta Therapeutics all-time high quarterly cash flow from financing activities is $549.25 M
What is Sarepta Therapeutics quarterly CFF year-on-year change?
Over the past year, SRPT quarterly cash flow from financing activities has changed by +$11.81 M (+608.03%)
What is Sarepta Therapeutics TTM cash flow from financing activities?
The current TTM CFF of SRPT is $77.76 M
What is the all time high TTM CFF for Sarepta Therapeutics?
Sarepta Therapeutics all-time high TTM cash flow from financing activities is $921.87 M
What is Sarepta Therapeutics TTM CFF year-on-year change?
Over the past year, SRPT TTM cash flow from financing activities has changed by -$47.25 M (-37.80%)